NHS
Pan Mersey
Area Prescribing Committee

FILGOTINIB tablets (Jyseleca® ▼) for moderate to severe rheumatoid arthritis

The Pan Mersey Area Prescribing Committee recommends the prescribing of FILGOTINIB tablets (Jyseleca® ▼), by specialists only, for moderate to severe rheumatoid arthritis in accordance with NICE TA676.

RED

NICE technology appraisal (TA) 676 recommends filgotinib, with methotrexate **or** as monotherapy when methotrexate is contraindicated or not tolerated, as an option for treating active rheumatoid arthritis (RA) in adults whose disease has responded inadequately to intensive therapy with 2 or more conventional disease modifying antirheumatic drugs (DMARDs), only if:

- disease is moderate or severe (a disease activity score [DAS28] of 3.2 or more) **and**
- the company provides filgotinib according to the commercial arrangement.

Filgotinib with methotrexate, **or** as monotherapy when methotrexate is contraindicated or not tolerated, is recommended as an option for treating active RA in adults whose disease has responded inadequately to or who cannot have other DMARDs, including at least 1 biological DMARD, only if:

- disease is severe (a DAS28 of more than 5.1) **and**
- they cannot have rituximab **and**
- the company provides filgotinib according to the commercial arrangement.

Filgotinib with methotrexate, **or** as monotherapy when methotrexate is contraindicated or not tolerated, is recommended as an option for treating active RA in adults whose disease has responded inadequately to rituximab and at least 1 biological DMARD, only if:

- disease is severe (a DAS28 of more than 5.1) **and**
- the company provides filgotinib according to the commercial arrangement.

Continue treatment only if there is a moderate response measured using European League Against Rheumatism (EULAR) criteria at 6 months after starting therapy. If this initial response is not maintained at 6 months, stop treatment.

If more than one treatment is suitable, start with the least expensive drug (taking into account administration costs, dose needed and product price per dose).

Prescribing and monitoring must be retained by a specialist in the management of RA.

NICE estimates that the cost of implementing NICE TA676 is £1,000 per 100,000 population in 2021/22 (once the PAS price and other associated costs are taken into account), rising to £10,000 per 100,000 population in 2022/23 and then £18,000 per 100,000 population in 2023/24 when steady state is assumed to have been reached.

References

1. National Institute for Health and Care Excellence. Technology Appraisal 676; Filgotinib for treating moderate to severe rheumatoid arthritis, 24 February 2021. Accessed online 26 February 2021.

Note: Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.